Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model.

Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model.
复制标题

DOI:
10.1016/j.canlet.2013.12.018
复制
发表时间:
2014-04-28
期刊:
影响因子:
9.7
通讯作者:
Sun, Lu-Zhe
Sun, Lu-Zhe
中科院分区:
医学1区
文献类型:
--
作者:
Biswas, Tanuka;Gu, Xiang;Yang, Junhua;Ellies, Lesley G.;Sun, Lu-Zhe

文献摘要

参考文献

被引文献

相似文献

先前的研究表明,TGF-β在转移性间充质样乳腺癌细胞中起肿瘤促进剂的作用,并且TGF-β抑制剂可以有效地消除这些模型中的几种模型中的肿瘤进展。在这里,我们报告了一个新的观察与使用遗传和药理学的方法,小鼠乳腺细胞注射模型在同基因和免疫受损的小鼠。我们发现,MMTV-PyMT衍生的Py 8119(一种间充质样小鼠乳腺肿瘤细胞系)中TGF-β受体II(TβRII)敲低导致同基因背景中原位肿瘤生长潜力增加,并在免疫受损背景中具有类似趋势。小分子TGF-β受体I激酶抑制剂的全身治疗诱导了Py 8119细胞心脏内接种后远处器官转移性定植增加的趋势,对同样来源于MMTV-PyMT肿瘤的管腔样Py 230细胞的定植几乎没有影响。总之,我们的数据表明,间充质样乳腺肿瘤中TGF-β信号传导的减弱不一定抑制其恶性潜能,抗TGF-β治疗干预需要更精确地鉴定具有功能性TGF-β信号传导指征的肿瘤中的分子标志物。
Previous studies have suggested that TGF-β functions as a tumor promoter in metastatic, mesenchymal-like breast cancer cells and that TGF-β inhibitors can effectively abrogate tumor progression in several of these models. Here we report a novel observation with the use of genetic and pharmacological approaches, and murine mammary cell injection models in both syngeneic and immune compromised mice. We found that TGF-β receptor II (TβRII) knockdown in the MMTV-PyMT derived Py8119, a mesenchymal-like murine mammary tumor cell line, resulted in increased orthotopic tumor growth potential in a syngeneic background and a similar trend in an immune compromised background. Systemic treatment with a small-molecule TGF-β receptor I kinase inhibitor induced a trend towards increased metastatic colonization of distant organs following intra cardiac inoculation of Py8119 cells, with little effect on the colonization of luminal-like Py230 cells, also derived from MMTV-PyMT tumors. Taken together, our data suggest that the attenuation of TGF-β signaling in mesenchymal-like mammary tumors does not necessarily inhibit their malignant potential, and anti-TGF-β therapeutic intervention requires greater precision in identifying molecular markers in tumors with an indication of functional TGF-β signaling.
DOI: 10.4049/jimmunol.168.12.6470
发表时间: 2002-06-15
影响因子: 4.4
作者:
Hagimoto, N;Kuwano, K;Hara, N
通讯作者: Hara, N
DOI: 10.1371/journal.pone.0010365
发表时间: 2010-04-28
期刊: PloS one
影响因子: 3.7
作者:
Bandyopadhyay A;Wang L;Agyin J;Tang Y;Lin S;Yeh IT;De K;Sun LZ
通讯作者: Sun LZ
DOI: 10.1038/sj.cgt.7700642
发表时间: 2003-11-01
影响因子: 6.4
作者:
London, CA;Sekhon, HS;Devi, GR
通讯作者: Devi, GR
DOI: 10.1016/j.ccr.2011.09.009
发表时间: 2011-11-15
期刊: Cancer cell
影响因子: 50.3
作者:
Labelle M;Begum S;Hynes RO
通讯作者: Hynes RO
DOI: 10.1158/0008-5472.can-12-0634
发表时间: 2012-09-15
期刊: Cancer research
影响因子: 11.2
作者:
Hezel AF;Deshpande V;Zimmerman SM;Contino G;Alagesan B;O'Dell MR;Rivera LB;Harper J;Lonning S;Brekken RA;Bardeesy N
通讯作者: Bardeesy N